Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF)

Basit Öğe Kaydı
dc.authorid0000-0002-0901-9192
dc.authorid0000-0002-9306-557X
dc.authorid0000-0001-9917-2678
dc.contributor.authorBalaban, Hatice Yasemin
dc.contributor.authorSumer, Hale
dc.contributor.authorŞimsek, Halis
dc.contributor.authorUs, Durdal
dc.contributor.authorTatar, Gonca
dc.date.accessioned2021-06-23T18:54:21Z
dc.date.available2021-06-23T18:54:21Z
dc.date.issued2006
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Hepatocyte growth factor (HGF) is not only an antiapoptotic and antifibrotic factor of liver, but it is also an adipokine. Serum HGF levels are strongly associated with liver diseases, obesity, insulin resistance (IR), and metabolic syndrome (MS). Non-alcoholic steatohepatitis (NASH) is the hepatic component of MS. To the best of our knowledge, serum HGF levels in patients with NASH have not been previously studied. Our aim was to elucidate the correlation of HGF with the clinical and histopathological parameters of NASH. Methods: The study group consisted of 26 patients (13 men) who had clinical diagnoses of NASH and underwent liver biopsies. Controls were 13 volunteers (3 men) with negative viral autoimmune markers, and with normal levels of serum lipids and liver enzymes. Results: Among the NASH patients, 14 (54%) were overweight and 10 (39%) had grade I-II obesity. All the patients had class 3-4 non-alcoholic fatty liver disease (NAFLD) except for 2 who had class 2 disease. All of the patients had Child's class A liver disease, and MS was present in 5 (19%) patients and 8 (31%) patients had Homeostasis Model Assessment of Insulin Resistance (HOMA) > 3. Serum HGF levels were similar in NASH patients (1.24 ± 1.09 pg/mL) and controls (0.86 ± 0.22 pg/mL) (p = 0.21). The levels of serum HGF did not differ between the patients with or without MS (1.65 ± 1.48 pg/mL and 1.04 ± 0.80 pg/mL, respectively, p=0.65). HGF was not correlated with the laboratory or histopathological parameters. Conclusions: Serum HGF levels were higher in NASH patients than in the controls, although it was statistically insignificant and a correlation with MS could not be detected in this study.en_US
dc.identifier.doi10.1016/s1665-2681(19)32027-7
dc.identifier.endpage114en_US
dc.identifier.issn1665-2681
dc.identifier.issue2en_US
dc.identifier.pmid16807517en_US
dc.identifier.scopus2-s2.0-33745040820en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage109en_US
dc.identifier.urihttps://doi.org/10.1016/s1665-2681(19)32027-7
dc.identifier.urihttps://hdl.handle.net/20.500.12491/4393
dc.identifier.volume5en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBalaban, Hatice Yasemin
dc.language.isoenen_US
dc.publisherFundacion Clinica Medica Suren_US
dc.relation.ispartofAnnals of Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatocyte Growth Factoren_US
dc.subjectInsulin Resistanceen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectNon-alcoholic Steatohepatitisen_US
dc.subjectObesityen_US
dc.titleMetabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu